Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Sci Rep ; 10(1): 6825, 2020 04 22.
Article in English | MEDLINE | ID: mdl-32321983

ABSTRACT

The threat of nuclear exposure is heightened and it is imperative to identify potential countermeasures for acute radiation syndrome. Currently no countermeasures have been approved for prophylactic administration. Effective countermeasures should function to increase survival in the short term as well as to increase the overall prognosis of an exposed individual long term. Here we describe the use of a promising radiation countermeasure, BBT-059, and the results of a long term mouse study (up to 12 months) in the male CD2F1 strain using 60Co gamma irradiation (~0.6 Gy/min, 7.5-12.5 Gy). We report the dose reduction factor of 1.28 for BBT-059 (0.3 mg/kg) compared to control administered 24 h prior to irradiation. In the long term study animals showed accelerated recovery in peripheral blood cell counts, bone marrow colony forming units, sternal cellularity and megakaryocyte numbers in drug treated mice compared to formulation buffer. In addition, increased senescence was observed in the kidneys of animals administered control or drug and exposed to the highest doses of radiation. Decreased levels of E-cadherin, LaminB1 and increased levels of Cyc-D and p21 in spleen lysates were observed in animals administered control. Taken together the results indicate a high level of protection following BBT-059 administration in mice exposed to lethal and supralethal doses of total body gamma-radiation.


Subject(s)
Interleukin-11/pharmacology , Radiation Exposure , Whole-Body Irradiation , Alkaline Phosphatase/blood , Animals , Aspartate Aminotransferases/blood , Blood Cell Count , Cadherins/metabolism , Clone Cells , Colony-Forming Units Assay , Dose-Response Relationship, Radiation , Gamma Rays , Hematopoietic Stem Cells/metabolism , Hematopoietic Stem Cells/radiation effects , Kidney/pathology , Kidney/radiation effects , Liver/pathology , Liver/radiation effects , Male , Mice , Organ Specificity/radiation effects , Survival Analysis
2.
Basic Clin Pharmacol Toxicol ; 125(3): 289-303, 2019 Sep.
Article in English | MEDLINE | ID: mdl-30843331

ABSTRACT

Sodium cyanide (NaCN) is a commonly and widely used industrial and laboratory chemical that is highly toxic. Its availability and rapid harmful/lethal effects combine to make cyanide a potential foodborne/waterborne intentional-poisoning hazard. Effective antidotes to cyanide poisoning are currently approved only for intravenous administration. Therefore, an effective cyanide antidote that can be administered intramuscularly in pre-hospital and/or mass-casualty settings is needed. Dimethyl trisulfide (DMTS) is a naturally occurring substance used as a flavour enhancer in foods. DMTS has shown antidotal efficacy in cyanide poisoning and is thought to act as both a sulphur donor and partial methaemoglobin inducer. In this study, an intramuscular injection of DMTS (6.25-200 mg/kg) was given to rats 1 minute after an oral dose of NaCN (98.2 mg/kg; twice the median lethal dose) to test the antidotal efficacy and safety of DMTS treatment. Toxic signs and survival were examined along with behavioural function (up to 30 hour after ingestion) using a previously established operant behavioural model. A large range of DMTS doses (6.25-100 mg/kg) increased survival after oral cyanide poisoning, and the lower DMTS doses (6.25-25 mg/kg) also proved to be behaviourally and physiologically safe. Larger DMTS doses (50-200 mg/kg) produced side effects (ie, inflammation and limping) that were more severe and protracted than those observed at lower DMTS doses. The 25 mg/kg DMTS proved to be the most efficacious (increasing survival from 20% to 75%) and also produced minimal side effects (eg, inflammation) that resolved within 24-72 hour. Thus, DMTS shows promise as an intramuscularly administered cyanide antidote useful for prompt pre-hospital or mass-casualty emergency medical treatment.


Subject(s)
Antidotes/administration & dosage , First Aid/methods , Poisoning/drug therapy , Sodium Cyanide/poisoning , Sulfides/administration & dosage , Administration, Oral , Animals , Antidotes/adverse effects , Behavior Observation Techniques , Behavior, Animal/drug effects , Disease Models, Animal , Humans , Injections, Intramuscular , Lethal Dose 50 , Male , Mass Casualty Incidents , Models, Neurological , Poisoning/mortality , Poisoning/psychology , Rats , Sodium Cyanide/administration & dosage , Sulfides/adverse effects , Survival Analysis , Treatment Outcome
3.
J Am Assoc Lab Anim Sci ; 56(6): 762-767, 2017 Nov 01.
Article in English | MEDLINE | ID: mdl-29256371

ABSTRACT

In this study, we compared the plasma concentrations of meloxicam in pediatric rat pups (ages: 7, 14, 21, and 28 d) with those of young adult rats. Adult rats received 1.34 mg/kg SC meloxicam to determine the target peak plasma concentration (Cmax) for comparison with the pediatric animals. Pediatric rats received 1.34 mg/kg SC meloxicam, and in all age groups, Cmax met or exceeded that in adults (11.5 ±2.7 µg/mL). Plasma concentrations were similar between male and female pups within age groups, and peak plasma concentration was achieved more rapidly in rat pups than adults. The analgesic efficacy of this dose was not evaluated in this study.


Subject(s)
Aging , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Rats/physiology , Thiazines/pharmacokinetics , Thiazoles/pharmacokinetics , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/blood , Drug Dosage Calculations , Female , Humans , Kidney/drug effects , Liver/drug effects , Male , Meloxicam , Rats/blood , Rats, Sprague-Dawley , Thiazines/administration & dosage , Thiazines/blood , Thiazoles/administration & dosage , Thiazoles/blood
SELECTION OF CITATIONS
SEARCH DETAIL